The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $107.86

Today's change+0.38 +0.35%
Updated November 21 4:04 PM EST. Delayed by at least 15 minutes.
 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $107.86

Today's change+0.38 +0.35%
Updated November 21 4:04 PM EST. Delayed by at least 15 minutes.

Johnson & Johnson up (U.S.)$0.38

Johnson & Johnson closed up Friday by (U.S.)$0.38 or 0.35% to (U.S.)$107.86. Shares have lost 0.28% over the last five days, but sit 1.49% below their 52-week high. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $108.73
  • Previous close(U.S.) $107.48
  • High(U.S.) $108.73
  • Low(U.S.) $107.62
  • Bid / Ask-- / --
  • YTD % change+17.76%
  • Volume8,417,378
  • Average volume (10-day)6,157,498
  • Average volume (1-month)7,225,641
  • Average volume (3-month)7,528,957
  • 52-week range(U.S.) $86.09 to (U.S.) $109.49
  • Beta0.56
  • Trailing P/E17.86×
  • P/E 1 year forward18.09×
  • Forward PEG2.73×
  • Indicated annual dividend(U.S.) $2.80
  • Dividend yield2.60%
  • Trailing EPS(U.S.) $6.04
Updated November 21 4:04 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+23.27%

Based on its net profit margin of 23.27%, Johnson & Johnson is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.24%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 28, 201409/28/2014Jun 29, 201406/29/2014Mar 30, 201403/30/2014Dec 29, 201312/29/2013
Revenue18,46719,49518,11518,355
Total other revenue--------
Total revenue18,46719,49518,11518,355
Gross profit13,06813,45612,66012,400
Total cost of revenue5,3996,0395,4555,955
Total operating expense11,65713,86912,69115,605
Selling / general / administrative5,4685,4815,1835,917
Research & development2,0232,0051,8312,411
Depreciation / amortization--------
Interest expense (income), net operating130128136134
Unusual expense (income)0418338
Other operating expenses, total-1,34717195850
Operating income6,8105,6265,4242,750
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax6,8105,6265,4242,750
Income after tax4,7494,3264,7273,519
Income tax, total2,0611,300697-769
Net income4,7494,3264,7273,519
Total adjustments to net income--------
Net income before extra. items4,7494,3264,7273,519
Minority interest------0
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items4,7494,3264,7273,519
Inc. avail. to common incl. extra. items4,7494,3264,7273,519
Diluted net income4,7494,3264,7273,519
Dilution adjustment--0----
Diluted weighted average shares2,8642,8742,8752,871
Diluted EPS excluding extraordinary itemsvalue per share1.661.511.641.23
Dividends per sharevalue per share0.700.700.660.66
Diluted normalized EPSvalue per share2.001.651.691.53